Publications by authors named "Diede Brunen"

Claim this Profile
A
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF colorectal tumors.
Ana Ruiz-Saenz, Chloe E Atreya, Changjun Wang, Bo Pan, Courtney A Dreyer, Diede Brunen

Nat Cancer· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.
Jean-Philippe Coppé, Miki Mori, Bo Pan, Christina Yau, Denise M Wolf, Diede Brunen

Nat Cell Biol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An ATG16L1-dependent pathway promotes plasma membrane repair and limits Listeria monocytogenes cell-to-cell spread.
Joel M J Tan, Nora Mellouk, Suzanne E Osborne, Dustin A Ammendolia, Diana N Dyer, Diede Brunen

Nat Microbiol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.
Liqin Wang, Rodrigo Leite de Oliveira, Sanne Huijberts, Evert Bosdriesz, Nora Pencheva, Diede Brunen

Cell· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.
Diede Brunen, Romy C de Vries, Cor Lieftink, Roderick L Beijersbergen, René Bernards

Mol Cancer Ther· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug therapy: Exploiting synthetic lethality to improve cancer therapy.
Diede Brunen, René Bernards

Nat Rev Clin Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data.
Subarna Sinha, Daniel Thomas, Steven Chan, Yang Gao, Diede Brunen

Nat Commun· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koos Koole, Diede Brunen, Pauline M W van Kempen, Rob Noorlag, Remco de Bree

Clin Cancer Res· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.
Diede Brunen, María José García-Barchino, Disha Malani, Noorjahan Jagalur Basheer, Cor Lieftink

Oncotarget· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TGF-β: an emerging player in drug resistance.
Diede Brunen, Stefan M Willems, Udo Kellner, Rachel Midgley, Iris Simon

Cell Cycle· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid temporal control of Foxp3 protein degradation by sirtuin-1.
Jorg van Loosdregt, Diede Brunen, Veerle Fleskens, Cornelieke E G M Pals, Eric W F Lam

PLoS One· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates.
Jens Verheyen, Chris Verhofstede, Elena Knops, Linos Vandekerckhove, Axel Fun, Diede Brunen

AIDS· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis